Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma

Nagato Satoh, Koichiro Asano, Katsuhiko Naoki, Koichi Fukunaga, Makiko Iwata, Minoru Kanazawa, Kazuhiro Yamaguchi

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Platelet-activating factor (PAF), a phospholipid with a wide range of proinflammatory actions, is immediately degraded and inactivated in vivo by PAF acetylhydrolase (PAF-AH). Surprisingly, 4% of the Japanese population lacks the extracellular isoform of this enzyme, plasma PAF-AH, due to a genetic missense (V279F) mutation. We studied the association of this mutation with asthma prevalence and phenotypes in the Japanese adult population. The allele frequency of V279F mutation was 18.6% in 279 patients with asthma (28.7% heterozygotes and 4.3 homozygotes) and 21.7% in 217 healthy subjects (32.3% heterozygotes and 5.5% homozygotes). V279F mutant allele prevalence was consistent regardless of asthma type (16.3% in atopic [n = 156] and 21.6% in nonatopic [n = 123]), or the severity of disease (21.7% in patients with mild [n = 97], 17.5% in those with moderate [n = 131], and 15.8% in those with severe [n = 51] asthma). Plasma PAF-AH activity was inversely proportional to the number of mutant alleles, and did not correlate with asthma prevalence, type, or severity. We concluded that plasma PAF-AH deficiency due to V279F mutation is not essential to the pathophysiology of asthma in the Japanese adult population.

Original languageEnglish
Pages (from-to)974-979
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume159
Issue number3
Publication statusPublished - 1999

Fingerprint

Platelet Activating Factor
Asthma
Homozygote
Heterozygote
Mutation
Alleles
Population
Missense Mutation
Gene Frequency
Platelet-Activating Factor Acetylhydrolase Deficiency
Phospholipids
Healthy Volunteers
Protein Isoforms
Phenotype
Enzymes

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma. / Satoh, Nagato; Asano, Koichiro; Naoki, Katsuhiko; Fukunaga, Koichi; Iwata, Makiko; Kanazawa, Minoru; Yamaguchi, Kazuhiro.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 159, No. 3, 1999, p. 974-979.

Research output: Contribution to journalArticle

Satoh, Nagato ; Asano, Koichiro ; Naoki, Katsuhiko ; Fukunaga, Koichi ; Iwata, Makiko ; Kanazawa, Minoru ; Yamaguchi, Kazuhiro. / Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma. In: American Journal of Respiratory and Critical Care Medicine. 1999 ; Vol. 159, No. 3. pp. 974-979.
@article{3004b79331a94e64876b5c5acacb5dd6,
title = "Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma",
abstract = "Platelet-activating factor (PAF), a phospholipid with a wide range of proinflammatory actions, is immediately degraded and inactivated in vivo by PAF acetylhydrolase (PAF-AH). Surprisingly, 4{\%} of the Japanese population lacks the extracellular isoform of this enzyme, plasma PAF-AH, due to a genetic missense (V279F) mutation. We studied the association of this mutation with asthma prevalence and phenotypes in the Japanese adult population. The allele frequency of V279F mutation was 18.6{\%} in 279 patients with asthma (28.7{\%} heterozygotes and 4.3 homozygotes) and 21.7{\%} in 217 healthy subjects (32.3{\%} heterozygotes and 5.5{\%} homozygotes). V279F mutant allele prevalence was consistent regardless of asthma type (16.3{\%} in atopic [n = 156] and 21.6{\%} in nonatopic [n = 123]), or the severity of disease (21.7{\%} in patients with mild [n = 97], 17.5{\%} in those with moderate [n = 131], and 15.8{\%} in those with severe [n = 51] asthma). Plasma PAF-AH activity was inversely proportional to the number of mutant alleles, and did not correlate with asthma prevalence, type, or severity. We concluded that plasma PAF-AH deficiency due to V279F mutation is not essential to the pathophysiology of asthma in the Japanese adult population.",
author = "Nagato Satoh and Koichiro Asano and Katsuhiko Naoki and Koichi Fukunaga and Makiko Iwata and Minoru Kanazawa and Kazuhiro Yamaguchi",
year = "1999",
language = "English",
volume = "159",
pages = "974--979",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3",

}

TY - JOUR

T1 - Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma

AU - Satoh, Nagato

AU - Asano, Koichiro

AU - Naoki, Katsuhiko

AU - Fukunaga, Koichi

AU - Iwata, Makiko

AU - Kanazawa, Minoru

AU - Yamaguchi, Kazuhiro

PY - 1999

Y1 - 1999

N2 - Platelet-activating factor (PAF), a phospholipid with a wide range of proinflammatory actions, is immediately degraded and inactivated in vivo by PAF acetylhydrolase (PAF-AH). Surprisingly, 4% of the Japanese population lacks the extracellular isoform of this enzyme, plasma PAF-AH, due to a genetic missense (V279F) mutation. We studied the association of this mutation with asthma prevalence and phenotypes in the Japanese adult population. The allele frequency of V279F mutation was 18.6% in 279 patients with asthma (28.7% heterozygotes and 4.3 homozygotes) and 21.7% in 217 healthy subjects (32.3% heterozygotes and 5.5% homozygotes). V279F mutant allele prevalence was consistent regardless of asthma type (16.3% in atopic [n = 156] and 21.6% in nonatopic [n = 123]), or the severity of disease (21.7% in patients with mild [n = 97], 17.5% in those with moderate [n = 131], and 15.8% in those with severe [n = 51] asthma). Plasma PAF-AH activity was inversely proportional to the number of mutant alleles, and did not correlate with asthma prevalence, type, or severity. We concluded that plasma PAF-AH deficiency due to V279F mutation is not essential to the pathophysiology of asthma in the Japanese adult population.

AB - Platelet-activating factor (PAF), a phospholipid with a wide range of proinflammatory actions, is immediately degraded and inactivated in vivo by PAF acetylhydrolase (PAF-AH). Surprisingly, 4% of the Japanese population lacks the extracellular isoform of this enzyme, plasma PAF-AH, due to a genetic missense (V279F) mutation. We studied the association of this mutation with asthma prevalence and phenotypes in the Japanese adult population. The allele frequency of V279F mutation was 18.6% in 279 patients with asthma (28.7% heterozygotes and 4.3 homozygotes) and 21.7% in 217 healthy subjects (32.3% heterozygotes and 5.5% homozygotes). V279F mutant allele prevalence was consistent regardless of asthma type (16.3% in atopic [n = 156] and 21.6% in nonatopic [n = 123]), or the severity of disease (21.7% in patients with mild [n = 97], 17.5% in those with moderate [n = 131], and 15.8% in those with severe [n = 51] asthma). Plasma PAF-AH activity was inversely proportional to the number of mutant alleles, and did not correlate with asthma prevalence, type, or severity. We concluded that plasma PAF-AH deficiency due to V279F mutation is not essential to the pathophysiology of asthma in the Japanese adult population.

UR - http://www.scopus.com/inward/record.url?scp=0032987419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032987419&partnerID=8YFLogxK

M3 - Article

VL - 159

SP - 974

EP - 979

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3

ER -